These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

145 related articles for article (PubMed ID: 33367304)

  • 1. The role of
    Şahin OE; Uslu-Beşli L; Asa S; Sağer S; Sönmezoğlu K
    Hell J Nucl Med; 2020; 23(3):321-329. PubMed ID: 33367304
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparison of ⁶⁸Ga-DOTATATE PET-CT, ¹⁸F-FDG PET-CT and 99mTc-(V)DMSA scintigraphy in the detection of recurrent or metastatic medullary thyroid carcinoma.
    Ozkan ZG; Kuyumcu S; Uzum AK; Gecer MF; Ozel S; Aral F; Adalet I
    Nucl Med Commun; 2015 Mar; 36(3):242-50. PubMed ID: 25369749
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparison of (68)Ga-DOTATATE and (18)F-fluorodeoxyglucose PET/CT in the detection of recurrent medullary thyroid carcinoma.
    Conry BG; Papathanasiou ND; Prakash V; Kayani I; Caplin M; Mahmood S; Bomanji JB
    Eur J Nucl Med Mol Imaging; 2010 Jan; 37(1):49-57. PubMed ID: 19662413
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Gallium-68 Dotatate PET/CT is superior to other imaging modalities in the detection of medullary carcinoma of the thyroid in the presence of high serum calcitonin.
    Tran K; Khan S; Taghizadehasl M; Palazzo F; Frilling A; Todd JF; Al-Nahhas A
    Hell J Nucl Med; 2015; 18(1):19-24. PubMed ID: 25679074
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The role of tumour biomarkers in choosing the appropriate positron emission tomography imaging in follow-up of medullary thyroid cancer.
    Şahin E; Elboğa U
    J Med Imaging Radiat Oncol; 2020 Dec; 64(6):756-761. PubMed ID: 32656989
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical impact of
    Tuncel M; Kılıçkap S; Süslü N
    Ann Nucl Med; 2020 Sep; 34(9):663-674. PubMed ID: 32602032
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The Clinical Utility of Gallium-68-DOTATATE Positron Emission Tomography Scanning in Medullary Thyroid Cancer.
    Gild ML; Kumar S; Fuchs TL; Glover A; Sidhu S; Sywak M; Tsang V; Gill AJ; Robinson BG; Schembri G; Clifton-Bligh RJ; Hoang J
    Endocr Pract; 2024 Mar; 30(3):218-224. PubMed ID: 38103829
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [(68)Ga]DOTATATE PET/MRI and [(18)F]FDG PET/CT are complementary and superior to diffusion-weighted MR imaging for radioactive-iodine-refractory differentiated thyroid cancer.
    Vrachimis A; Stegger L; Wenning C; Noto B; Burg MC; Konnert JR; Allkemper T; Heindel W; Riemann B; Schäfers M; Weckesser M
    Eur J Nucl Med Mol Imaging; 2016 Sep; 43(10):1765-72. PubMed ID: 27059853
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Evaluation of F-18 DOPA PET/CT in the detection of recurrent or metastatic medullary thyroid carcinoma: comparison with GA-68 DOTA-TATE PET/CT.
    Asa S; Sonmezoglu K; Uslu-Besli L; Sahin OE; Karayel E; Pehlivanoglu H; Sager S; Kabasakal L; Ocak M; Sayman HB
    Ann Nucl Med; 2021 Aug; 35(8):900-915. PubMed ID: 33993425
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Assessing Krenning's score on 68 Ga-DOTATATE PET-CT and miPSMA score on 68 Ga-PSMA-11 PET-CT in TENIS: a comparison with FDG PET/CT and examining the feasibility of targeted radionuclide therapy.
    Sonavane S; Salvi O; Asopa RV; Basu S
    Nucl Med Commun; 2024 Aug; 45(8):690-701. PubMed ID: 38832433
    [TBL] [Abstract][Full Text] [Related]  

  • 11.
    Souteiro P; Gouveia P; Ferreira G; Belo S; Costa C; Carvalho D; Duarte H; Sampaio IL
    Endocrine; 2019 May; 64(2):322-329. PubMed ID: 30684230
    [TBL] [Abstract][Full Text] [Related]  

  • 12. MIB-1 Index-Stratified Assessment of Dual-Tracer PET/CT with
    Sampathirao N; Basu S
    J Nucl Med Technol; 2017 Mar; 45(1):34-41. PubMed ID: 28154019
    [TBL] [Abstract][Full Text] [Related]  

  • 13.
    Pajak C; Cadili L; Nabata K; Wiseman SM
    Am J Surg; 2022 Aug; 224(2):670-675. PubMed ID: 35382933
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Diagnostic utility of PET/CT with
    Romero-Lluch AR; Cuenca-Cuenca JI; Guerrero-Vázquez R; Martínez-Ortega AJ; Tirado-Hospital JL; Borrego-Dorado I; Navarro-González E
    Eur J Nucl Med Mol Imaging; 2017 Nov; 44(12):2004-2013. PubMed ID: 28646462
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prospective evaluation of 68Ga-DOTA-NOC PET-CT in patients with recurrent medullary thyroid carcinoma: comparison with 18F-FDG PET-CT.
    Naswa N; Sharma P; Suman Kc S; Lata S; Kumar R; Malhotra A; Bal C
    Nucl Med Commun; 2012 Jul; 33(7):766-74. PubMed ID: 22531829
    [TBL] [Abstract][Full Text] [Related]  

  • 16. THE COMBINED USE OF CALCITONIN DOUBLING TIME AND
    Yang JH; Camacho CP; Lindsey SC; Valente FOF; Andreoni DM; Yamaga LY; Wagner J; Biscolla RPM; Maciel RMB
    Endocr Pract; 2017 Aug; 23(8):942-948. PubMed ID: 28614009
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparison of
    Yu HN; Liu L; Chen QS; He Q; Li YS; Wang Y; Gao S
    Orthop Surg; 2021 May; 13(3):791-798. PubMed ID: 33709632
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Superiority of
    Jha A; Ling A; Millo C; Gupta G; Viana B; Lin FI; Herscovitch P; Adams KT; Taïeb D; Metwalli AR; Linehan WM; Brofferio A; Stratakis CA; Kebebew E; Lodish M; Civelek AC; Pacak K
    Eur J Nucl Med Mol Imaging; 2018 May; 45(5):787-797. PubMed ID: 29204718
    [TBL] [Abstract][Full Text] [Related]  

  • 19. F-18-Dopa Positron Emission Tomography/Computed Tomography Is More Sensitive Than Whole-Body Magnetic Resonance Imaging for the Localization of Persistent/Recurrent Disease of Medullary Thyroid Cancer Patients.
    Terroir M; Caramella C; Borget I; Bidault S; Dromain C; El Farsaoui K; Deandreis D; Grimaldi S; Lumbroso J; Berdelou A; Hadoux J; Hescot S; Hartl D; Baudin E; Schlumberger M; Leboulleux S
    Thyroid; 2019 Oct; 29(10):1457-1464. PubMed ID: 31530235
    [No Abstract]   [Full Text] [Related]  

  • 20. More advantages in detecting bone and soft tissue metastases from prostate cancer using
    Pianou NK; Stavrou PZ; Vlontzou E; Rondogianni P; Exarhos DN; Datseris IE
    Hell J Nucl Med; 2019; 22(1):6-9. PubMed ID: 30843003
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.